Adaptive Biotechnologies (ADPT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ADPT Adaptive Biotechnologies

Watchlist

5.930
-0.560-8.63%

Close Nov 12 16:00 ET

5.960
+0.030+0.51%

Post 18:05 ET

875.15MMarket Cap-4425P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Scotiabank Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10
Moomoo NewsNov 12 07:36 ET · Ratings
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors
Simply Wall StNov 12 06:30 ET
Adaptive Biotechnologies Is Maintained at Overweight by Piper Sandler
Dow JonesNov 11 08:00 ET · Ratings
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $7
Moomoo NewsNov 11 07:31 ET · Ratings
J.P. Morgan Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $7
Moomoo NewsNov 11 07:31 ET · Ratings
Express News | Adaptive Biotechnologies Corp : Piper Sandler Raises Target Price to $7 From $6
ReutersNov 10 23:14 ET

Comments

Jaguar8

Aug 29 07:03

NEWS

$Adaptive Biotechnologies (ADPT.US)$
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
Adaptive Biotechnologies (Nasdaq: ADPT) has announced that its clonoSEQ® test has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union. This makes clonoSEQ the first IVDR-certified test for detecting minimal residual disease (MRD) in patients with lymphoid malignancies. The certification allows for broad use in assessing MRD status and chang...

TechWhiz

Jun 28 18:55

Good volume move up. Small caps like adaptive biotechnologies are moving after Nvidia and other big techs took a break.
Should see higher prices from here.

Trytosaveabit

May 31 06:39

Watching for data outa this!

$Adaptive Biotechnologies (ADPT.US)$ Adaptive Biotechnologies Says Its Next-generation Sequencing-based ClonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting
The meeting will be taking place from May 31-June 4 in Chicago. Company will also present at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually...

TechWhiz

May 4 08:24

Adaptive biotech earnings?

Will they be as good as Ardelyx? Hopefully.
Ardelyx price skyrocketed after good earnings. The tide could be turning for biopharm, biotech stocks.

Moomoo AI

Mar 8 04:26

Recent insider selling at Adaptive Biotechnologies and lack of insider buying in the past year may deter potential investors, despite insiders owning significant shares.